JP2024516998A5 - - Google Patents

Info

Publication number
JP2024516998A5
JP2024516998A5 JP2023567923A JP2023567923A JP2024516998A5 JP 2024516998 A5 JP2024516998 A5 JP 2024516998A5 JP 2023567923 A JP2023567923 A JP 2023567923A JP 2023567923 A JP2023567923 A JP 2023567923A JP 2024516998 A5 JP2024516998 A5 JP 2024516998A5
Authority
JP
Japan
Prior art keywords
combination
inhibitor
cycloalkyl
egfr
alkylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023567923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516998A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/027693 external-priority patent/WO2022235815A1/en
Publication of JP2024516998A publication Critical patent/JP2024516998A/ja
Publication of JP2024516998A5 publication Critical patent/JP2024516998A5/ja
Pending legal-status Critical Current

Links

JP2023567923A 2021-05-05 2022-05-04 Shp2阻害剤とegfrチロシンキナーゼ阻害剤とを含む併用療法 Pending JP2024516998A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163184697P 2021-05-05 2021-05-05
US63/184,697 2021-05-05
US202263320991P 2022-03-17 2022-03-17
US63/320,991 2022-03-17
PCT/US2022/027693 WO2022235815A1 (en) 2021-05-05 2022-05-04 Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2024516998A JP2024516998A (ja) 2024-04-18
JP2024516998A5 true JP2024516998A5 (cg-RX-API-DMAC10.html) 2025-05-14

Family

ID=83932546

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023567923A Pending JP2024516998A (ja) 2021-05-05 2022-05-04 Shp2阻害剤とegfrチロシンキナーゼ阻害剤とを含む併用療法

Country Status (8)

Country Link
US (1) US20220370456A1 (cg-RX-API-DMAC10.html)
EP (1) EP4334317A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024516998A (cg-RX-API-DMAC10.html)
AU (1) AU2022270106A1 (cg-RX-API-DMAC10.html)
CA (1) CA3217092A1 (cg-RX-API-DMAC10.html)
IL (1) IL308225A (cg-RX-API-DMAC10.html)
MX (1) MX2023012929A (cg-RX-API-DMAC10.html)
WO (1) WO2022235815A1 (cg-RX-API-DMAC10.html)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
WO2015050345A1 (en) 2013-10-01 2015-04-09 Lg Electronics Inc. Control apparatus for mobile terminal and control method thereof
PT3468972T (pt) 2016-06-14 2020-08-21 Novartis Ag Compostos e composições para inibir a atividade da shp2
CN110730678B (zh) * 2017-01-10 2022-07-15 诺华股份有限公司 包含alk抑制剂和shp2抑制剂的药物组合
CN117263942A (zh) * 2018-03-21 2023-12-22 传达治疗有限公司 Shp2磷酸酶抑制剂及其使用方法
CN111647000B (zh) * 2019-03-04 2021-10-12 勤浩医药(苏州)有限公司 吡嗪类衍生物及其在抑制shp2中的应用
US11033547B2 (en) * 2019-03-07 2021-06-15 Merck Patent Gmbh Carboxamide-pyrimidine derivatives as SHP2 antagonists
EP4288057A4 (en) * 2021-02-05 2025-03-12 Verastem, Inc. Combination therapy for treating abnormal cell growth
WO2022235822A1 (en) * 2021-05-05 2022-11-10 Huabio International, Llc Shp2 inhibitor monotherapy and uses thereof
CA3217084A1 (en) * 2021-05-05 2022-11-10 Farbod Shojaei Combination therapies comprising shp2 inhibitors and pd-1 inhibitors

Similar Documents

Publication Publication Date Title
JP2024516997A5 (cg-RX-API-DMAC10.html)
AU2009279771B2 (en) Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
TWI833055B (zh) 抗癌化合物及其醫藥用途
JP2018504418A5 (cg-RX-API-DMAC10.html)
EP2591805A1 (en) Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
JP2020536971A5 (cg-RX-API-DMAC10.html)
CN114364677A (zh) 作为toll-样受体激动剂的咪唑并[4,5-c]吡啶衍生物
US20250262214A1 (en) Intermittent dosing regimen for azenosertib in treating cancer
JPWO2020032105A5 (cg-RX-API-DMAC10.html)
JP2024125139A5 (cg-RX-API-DMAC10.html)
JP2024516037A5 (cg-RX-API-DMAC10.html)
EP3125901B1 (en) Derivatives of cephalosporin for treating cancer
JP2024515061A5 (cg-RX-API-DMAC10.html)
JP2026506975A (ja) 薬物コンジュゲートの腫瘍疾患治療における使用および方法
JP2022550040A5 (cg-RX-API-DMAC10.html)
CN101175495B (zh) 抗癌化合物的组合
CN1879619A (zh) 癌症治疗
TW202604574A (zh) 抗體藥物偶聯物在預防或治療疾病中的應用
WO2023212181A1 (en) Compounds for proliferative disorders
JP6553726B2 (ja) 腫瘍治療剤
HK40113079A (en) Antineoplastic combinations of neratinib and capecitabine
JP2023511039A (ja) 組み合わせ療法
HK40072488A (en) Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonists
RU2020138336A (ru) Ингибиторы рецепторов erbb
HK1239521A1 (en) Antineoplastic combinations of neratinib and capecitabine